CL2019000392A1 - Métodos para detectar aav. - Google Patents

Métodos para detectar aav.

Info

Publication number
CL2019000392A1
CL2019000392A1 CL2019000392A CL2019000392A CL2019000392A1 CL 2019000392 A1 CL2019000392 A1 CL 2019000392A1 CL 2019000392 A CL2019000392 A CL 2019000392A CL 2019000392 A CL2019000392 A CL 2019000392A CL 2019000392 A1 CL2019000392 A1 CL 2019000392A1
Authority
CL
Chile
Prior art keywords
methods
aav
particles
heterogeneity
particle
Prior art date
Application number
CL2019000392A
Other languages
English (en)
Inventor
Xiaoying Jin
Catherine R O'riordan
Lin Liu
Kate Zhang
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59762045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019000392(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CL2019000392A1 publication Critical patent/CL2019000392A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Photoreceptors In Electrophotography (AREA)

Abstract

EN LA PRESENTE MEMORIA SE PROPORCIONAN MÉTODOS PARA DETERMINAR EL SEROTIPO DE UNA PARTÍCULA DE VIRUS Y/O PARA DETERMINAR LA HETEROGENEIDAD DE UNA PARTÍCULA DE VIRUS (P. EJ., UNA PARTÍCULA DE AAV). EN OTRAS REALIZACIONES, LA INVENCIÓN PROPORCIONA MÉTODOS PARA DETERMINAR LA HETEROGENEIDAD DE PARTÍCULAS DE AAV. EN ALGUNOS ASPECTOS, LA INVENCIÓN PROPORCIONA PARTÍCULAS VIRALES (P. EJ., PARTÍCULAS DE AAVR) CON ESTABILIDAD MEJORADA Y/O EFICIENCIA DE LA TRANSDUCCIÓN MEJORADA MEDIANTE EL INCREMENTO DE LA ACETILACIÓN Y/O DESAMIDACIÓN DE LAS PROTEÍNAS DE LA CÁPSIDE.
CL2019000392A 2016-08-15 2019-02-13 Métodos para detectar aav. CL2019000392A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662375314P 2016-08-15 2016-08-15

Publications (1)

Publication Number Publication Date
CL2019000392A1 true CL2019000392A1 (es) 2019-05-10

Family

ID=59762045

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019000392A CL2019000392A1 (es) 2016-08-15 2019-02-13 Métodos para detectar aav.
CL2019002912A CL2019002912A1 (es) 2016-08-15 2019-10-14 Métodos para detectar aav. (divisional solicitud 201900392).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2019002912A CL2019002912A1 (es) 2016-08-15 2019-10-14 Métodos para detectar aav. (divisional solicitud 201900392).

Country Status (23)

Country Link
US (2) US11698377B2 (es)
EP (2) EP3851449A1 (es)
JP (3) JP7021191B2 (es)
KR (3) KR102538037B1 (es)
CN (1) CN110168080B (es)
AU (2) AU2017312951B2 (es)
BR (1) BR112019002934A2 (es)
CA (1) CA3033856A1 (es)
CL (2) CL2019000392A1 (es)
CR (1) CR20190127A (es)
CY (1) CY1124364T1 (es)
DK (1) DK3497207T3 (es)
ES (1) ES2863674T3 (es)
HU (1) HUE053747T2 (es)
IL (1) IL264819B1 (es)
MA (1) MA55748A (es)
MX (2) MX2019001938A (es)
PH (1) PH12019500316A1 (es)
SG (2) SG11201901221YA (es)
TN (1) TN2019000047A1 (es)
TW (2) TW202309068A (es)
WO (1) WO2018035059A1 (es)
ZA (1) ZA201900945B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
SG11201907714UA (en) 2017-02-28 2019-09-27 Univ Pennsylvania Adeno-associated virus (aav) clade f vector and uses therefor
KR20210006327A (ko) * 2018-02-27 2021-01-18 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 캡시드 탈아미드화가 감소된 신규 아데노-연관 바이러스(aav) 벡터 및 이의 용도
CA3091806A1 (en) * 2018-02-27 2019-09-06 The Trustees Of The University Of Pennsylvania Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
US20210010028A1 (en) * 2018-03-06 2021-01-14 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
US11391707B2 (en) * 2018-07-27 2022-07-19 Waters Technologies Corporation Liquid chromatography/mass spectrometry methods for the analysis of polar molecules
US20210317478A1 (en) * 2018-08-21 2021-10-14 Massachusetts Eye And Ear Infirmary Compositions and methods for modulating transduction efficiency of adeno-associated viruses
EP3870976B1 (en) * 2018-10-25 2023-11-29 Regeneron Pharmaceuticals, Inc. Methods for analysis of viral capsid protein composition
US20230204595A1 (en) 2020-01-03 2023-06-29 Sarepta Therapeutics, Inc. Methods for analyzing aav capsid proteins
JP2023513004A (ja) 2020-01-29 2023-03-30 ジェンザイム・コーポレーション 眼科遺伝子療法のための改変されたアデノ随伴ウイルスカプシドタンパク質およびその使用方法
CN111517359B (zh) * 2020-04-23 2021-08-20 江南大学 一种手性硫化铜超粒子的合成方法
RU2748540C1 (ru) * 2021-02-08 2021-05-26 Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" Способ детектирования вируса SARS-CoV-2 методом масс-спектрометрии
EP4295158A1 (en) * 2021-02-19 2023-12-27 Waters Technologies Corporation Methods for peptide mapping of adeno-associated virus (aav) proteins
WO2022224965A1 (ja) * 2021-04-20 2022-10-27 株式会社ユニバーサル・バイオサンプリング 検体保持カード及びそれを用いた検体の検査方法
WO2023287724A1 (en) * 2021-07-12 2023-01-19 Regeneron Pharmaceuticals, Inc. Online native mass spectrometry methods for assaying viral particles
KR20240031375A (ko) * 2021-07-12 2024-03-07 리제너론 파아마슈티컬스, 인크. 2차원 액체 크로마토그래피-질량 분광분석을 사용하여 바이러스 입자를 특성화하는 방법
CN113552349B (zh) * 2021-07-30 2022-07-19 上海勉亦生物科技有限公司 Aav蛋白外壳的检测方法
WO2023132338A1 (ja) * 2022-01-06 2023-07-13 富士フイルム株式会社 タンパク質における糖が結合したアミノ酸部位を同定する方法、及びキット

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204059B1 (en) * 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
WO1998010088A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
JP4827353B2 (ja) 1999-08-09 2011-11-30 ターゲティッド ジェネティクス コーポレイション 鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大
ES2256265T3 (es) 2000-06-01 2006-07-16 University Of North Carolina At Chapel Hill Vectores de parvovirus duplicados.
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
NZ600121A (en) 2001-11-13 2013-12-20 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
NZ561656A (en) 2002-05-01 2009-03-31 Univ Florida Improved rAAV expression systems for genetic modification of specific capsid proteins
EP1586107A2 (en) * 2002-11-22 2005-10-19 Caprion Pharmaceuticals, Inc. Constellation mapping and uses thereof
WO2004075861A2 (en) 2003-02-26 2004-09-10 Children's Hospital, Inc. Recombinant adeno-associated virus production
ES2521682T3 (es) 2003-05-21 2014-11-13 Genzyme Corporation Procedimientos para producir preparaciones de viriones de AAV recombinantes sustancialmente exentas de cápsidas vacías
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
US9441244B2 (en) * 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
EP2311967B1 (en) * 2005-10-20 2017-09-20 UniQure IP B.V. Improved AAV vectors produced in insect cells
WO2007120542A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
EP2342567A1 (en) 2008-09-19 2011-07-13 Charité Universitätsmedizin Berlin Identification and characterisation of recombinant viral gene therapy vectors
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
CA3077531C (en) 2009-06-16 2022-09-20 Genzyme Corporation Improved methods for purification of recombinant aav vectors
EP2826860B1 (en) 2010-04-23 2018-08-22 University of Massachusetts CNS targeting AAV vectors and methods of use thereof
US20130217789A1 (en) * 2010-09-03 2013-08-22 North Carolina Central University Biodegradable liquogel and ph sensitive nanocarriers
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
ES2724800T3 (es) 2011-02-17 2019-09-16 Univ Pennsylvania Composiciones y métodos para alterar la especificidad de tejido y mejorar la transferencia génica mediada por AAV9
US9169299B2 (en) 2011-08-24 2015-10-27 The Board Of Trustees Of The Leleand Stanford Junior University AAV capsid proteins for nucleic acid transfer
IN2014DN08812A (es) * 2012-04-18 2015-05-22 Philadelphia Children Hospital
US20140017716A1 (en) * 2012-07-11 2014-01-16 Siscapa Assay Technologies, Inc. Proteolytic digestion kit with dried reagents
GB201401707D0 (en) 2014-01-31 2014-03-19 Sec Dep For Health The Adeno-associated viral vectors
US10837027B2 (en) * 2014-03-10 2020-11-17 Uniqure Ip B.V. Further improved AAV vectors produced in insect cells

Also Published As

Publication number Publication date
ES2863674T3 (es) 2021-10-11
JP2022064980A (ja) 2022-04-26
AU2017312951A1 (en) 2019-04-04
KR102538037B1 (ko) 2023-05-30
RU2019107207A (ru) 2020-09-15
DK3497207T3 (da) 2021-03-22
CR20190127A (es) 2019-06-25
MA55748A (fr) 2022-03-02
KR102425289B1 (ko) 2022-07-27
JP2019533803A (ja) 2019-11-21
US20210041451A1 (en) 2021-02-11
SG11201901221YA (en) 2019-03-28
KR20220107327A (ko) 2022-08-02
AU2024200349A1 (en) 2024-02-08
BR112019002934A2 (pt) 2019-05-14
IL264819A (es) 2019-04-30
US20240044910A1 (en) 2024-02-08
WO2018035059A9 (en) 2019-03-14
US11698377B2 (en) 2023-07-11
EP3497207B1 (en) 2021-01-06
KR20230078834A (ko) 2023-06-02
CL2019002912A1 (es) 2020-03-06
CY1124364T1 (el) 2022-07-22
MX2023009081A (es) 2023-08-08
ZA201900945B (en) 2021-06-30
JP7021191B2 (ja) 2022-02-16
TW201825898A (zh) 2018-07-16
JP2024023460A (ja) 2024-02-21
TN2019000047A1 (en) 2020-07-15
CN110168080B (zh) 2024-05-31
PH12019500316A1 (en) 2019-08-05
KR20190039253A (ko) 2019-04-10
TW202309068A (zh) 2023-03-01
RU2019107207A3 (es) 2021-04-29
CA3033856A1 (en) 2018-02-22
EP3497207A1 (en) 2019-06-19
TWI781953B (zh) 2022-11-01
EP3851449A1 (en) 2021-07-21
HUE053747T2 (hu) 2021-07-28
AU2017312951B2 (en) 2024-02-08
WO2018035059A1 (en) 2018-02-22
IL264819B1 (en) 2024-06-01
MX2019001938A (es) 2019-07-04
SG10201913002QA (en) 2020-03-30
CN110168080A (zh) 2019-08-23

Similar Documents

Publication Publication Date Title
CL2019000392A1 (es) Métodos para detectar aav.
MX2022006652A (es) Proteinas de capside modificadas para un suministro mejorado de vectores de parvovirus.
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
CL2017002731A1 (es) Adenovirus oncolítico que codifica una proteína b7
WO2017066764A3 (en) Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
TR201901582T4 (tr) Kapsid
MX2019000252A (es) Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos.
PE20150163A1 (es) Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav
CO2018007203A2 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
CL2017003096A1 (es) Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis
EA201792500A1 (ru) Aav-опосредованная экспрессия антител против гриппа и способы их использования
BR112019012343A2 (pt) anticorpos il-11ra
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201791562A1 (ru) Антигены цитомегаловируса и их применения
EA201890527A1 (ru) Терапевтические вакцины против hpv18
EA201891460A1 (ru) Композиция дендритных клеток
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
UY36522A (es) Ultracentrifugación analítica para la caracterización de partículas virales recombinantes
CY1122644T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
CY1124707T1 (el) Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων)
MX2017008096A (es) Pestivirus.